Inclusion criteria:

        In the dose escalation part: patients with high MET tumor expression, evaluable or
        measurable solid tumors for which no standard therapy is available.

        In the expansion cohorts: in the first cohort, patients with diagnosed MET gene amplified
        including NSCLC patients and measurable tumors for which no standard therapy is available
        will be eligible. In the second cohort, patients with advanced P-MET positive measurable
        solid tumor without MET- gene amplification for which no standard therapy is available will
        be eligible.

        Exclusion criteria:

        Patient less than 18 years old. ECOG performance status >2. Any serious active disease or
        co-morbid condition, which, in the opinion of the Investigator, may interfere with the
        safety or the compliance with the study.

        Poor bone marrow reserve as defined by absolute neutrophil count <1.5 x 10^9/L or platelets
        <100 x 10^9/L.

        Poor organ function as defined by one of the following:

          -  Total bilirubin >1.5 x ULN

          -  AST, ALT, alkaline phosphatase >2.5 x ULN or >5 x ULN in case of documented liver
             metastasis. Alkaline phosphatase up to 5 x ULN in case of osteolytic bone metastasis
             without liver metastases is allowed

          -  Serum creatinine >1.5 x ULN or

          -  Serum creatinine between 1.0 and 1.5 x ULN associated with calculated creatinine
             clearance <60 mL/min

          -  Proteinuria >500 mg/24H Pregnant or breast-feeding women. No use of effective birth
             control methods, when applicable. No measurable or evaluable tumor lesion in the Dose
             Escalation part, and no measurable lesions in the expansion cohorts.

        Brain metastasis (other than totally resected or previously pre-irradiated and no
        progressive/relapsing) or lepto-meningeal carcinomatosis.

        No resolution of any specific toxicities (excluding alopecia) related to any prior
        anti-cancer therapy to grade ≤1 according to the NCI CTCAE v.4.03.

        Wash out period of less than 3 weeks from previous antitumor therapy or any investigational
        treatment (and less than 6 weeks in case of prior nitroso-urea and or mitomycin C
        treatment).

        Any surgery with major risk of bleeding performed less than 10 days prior to study
        treatment administration.

        Any other severe underlying medical conditions, which could impair the ability to
        participate in the study or the interpretation of its results.

        Patients treated with potent CYP3A inhibitor unless it can be discontinued at least 2 weeks
        prior to study treatment or 5 elimination half-life, whichever is the longest.

        Patients treated with potent and moderate CYP3A inducers unless it can be discontinued at
        least 2 weeks prior to study treatment or 5 elimination half-life, whichever is the
        longest. Patients treated with weak CYP3A inducers such as dexamethasone are eligible.

        Known hypersensitivity or any adverse event related to the study drug excipient.

        Prior treatment with any compound in the same class. Mean QTc interval prolongation.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.